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Genetic studies have demonstrated the involvement of the complement regulator factor H in nondiarrheal, non-
verocytotoxin (i.e., atypical) cases of hemolytic uremic syndrome. Different factor H mutations have been identified
in 10%–30% of patients with atypical hemolytic uremic syndrome (aHUS), and most of these mutations alter
single amino acids in the C-terminal region of factor H. Although these mutations are considered to be responsible
for the disease, the precise role that factor H plays in the pathogenesis of aHUS is unknown. We report here the
structural and functional characterization of three different factor H proteins purified from the plasma of patients
with aHUS who carry the factor H mutations W1183L, V1197A, or R1210C. Structural anomalies in factor H
were found only in R1210C carriers; these individuals show, in their plasma, a characteristic high-molecular-weight
factor H protein that results from the covalent interaction between factor H and human serum albumin. Most
important, all three aHUS-associated factor H proteins have a normal cofactor activity in the proteolysis of fluid-
phase C3b by factor I but show very low binding to surface-bound C3b. This functional impairment was also
demonstrated in recombinant mutant factor H proteins expressed in COS7 cells. These data support the hypothesis
that patients with aHUS carry a specific dysfunction in the protection of cellular surfaces from complement acti-
vation, offering new possibilities to improve diagnosis and develop appropriate therapies.
Introduction
Hemolytic uremic syndrome (HUS) is a microvasculature
disorder leading to microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure. Most cases
of HUS are associated with epidemics of diarrhea caused
by verocytotoxin-producing bacteria. There are cases of
HUS not associated with diarrhea, which are known as
“atypical HUS” (aHUS [MIM 134370; MIM 235400]).
Cases of aHUS are sometimes familial and generally have
a poor outcome (for review, see Ruggenenti and Remuzzi
1998). Recently, it has been demonstrated that aHUS seg-
regates with the factor H gene locus (HF1) (Warwicker
et al. 1998) and that a significant number of patients with
aHUS (10%–30%) carry mutations in HF1 (Warwicker
et al. 1998; Buddles et al. 2000; Caprioli et al. 2001;
Pe´rez-Caballero et al. 2001; Richards et al. 2001). Al-
though early studies suggested the association between
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aHUS and deficiencies of factor H (Thompson and Win-
terborn 1981; Pichette et al. 1994; Ohali et al. 1998;
Rougier et al. 1998), many patients with aHUS who have
mutations in HF1 present normal complement profiles
and have plasma levels of factor H that are either within
the normal range or elevated (Warwicker et al. 1998;
Caprioli et al. 2001; Pe´rez-Caballero et al. 2001; Rich-
ards et al. 2001).
Factor H is a plasma protein (molecular weight
155,000 Da) that controls activation of the comple-
ment system in the fluid phase and on cellular sur-
faces. Factor H binds to C3b, accelerates the decay
of the alternative-pathway C3 convertase, and acts
as a cofactor in the factor I–mediated proteolytic in-
activation of C3b (Weiler et al. 1976; Pangburn et al.
1977). It can also interact with polyanionic molecules
(sialic acids or glycosaminoglycans) on certain cellular
surfaces, conferring to them resistance to damage as a
consequence of complement activation through the al-
ternative pathway (Meri and Pangburn 1990; Pang-
burn et al. 1991, 2000). Factor H is composed of 20
repetitive units of 60 amino acids, and these units are
named “short consensus repeats” (SCRs) (Ripoche et
al. 1988). The functional domains in the factor H mol-
ecule have been delineated elsewhere (Sharma and
Pangburn 1996). Factor H has three binding sites for
C3b, in SCR1-4, SCR6-10, and SCR16-20. The C3b
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Figure 1 Functional domains and mutations in the factor H mol-
ecule, showing a diagram of the structure of human factor H with the
20 SCRs. Functional domains are indicated schematically. The location
of the missense mutations thus far characterized in patients with aHUS
(Warwicker et al. 1998; Caprioli et al. 2001; Pe´rez-Caballero et al. 2001;
Richards et al. 2001; Perkins and Goodship 2002; Remuzzi et al. 2002b)
is indicated, to illustrate that they are clustered in a specific factor H
region that has been involved in the control of C3b deposited on surfaces.
The mutations analyzed in the present article are indicated by asterisks.
binding site in SCR1-4 is the only site essential for the
cofactor activity, but deletion of any of the C3b bind-
ing sites significantly decreases factor H binding to
C3b deposited on cellular surfaces (Sharma and Pang-
burn 1996). In addition, SCR7, SCR13, and SCR16-
20 have been found to contain heparin and/or sialic
acid binding sites (Pangburn et al. 1991; Blackmore
et al. 1996, 1998; Ram et al. 1998).
The mutational screening of the HF1 gene in inde-
pendent series of patients with aHUS has resulted in the
identification of a remarkable clustering of missense mu-
tations in the SCR16-20 region of factor H (Caprioli et
al. 2001; Pe´rez-Caballero et al. 2001; Richards et al.
2001) (fig. 1). This region is involved in the binding of
factor H to C3b deposited on cellular surfaces (Pang-
burn et al. 2000). Therefore, we and others have sug-
gested a specific dysfunction in the protection of cellular
surfaces by factor H in patients with aHUS (Caprioli et
al. 2001; Pe´rez-Caballero et al. 2001; Richards et al.
2001; Zipfel 2001; Perkins and Goodship 2002).
To gain further insight into the pathogenesis of aHUS,
we have purified factor H from the plasma of patients
with aHUS, and we have produced recombinant aHUS-
associated factor H mutant proteins in COS7 cells. The
functional activity of the purified factor H proteins was
determined by utilization of two assays, analysis of the
cofactor activity in the proteolysis of fluid-phase C3b
by factor I, and analysis of the binding to surface-bound
C3b. Our results demonstrate that the aHUS-associated
factor H proteins have impaired binding to surface-
bound C3b, providing the first experimental evidence
that the missense mutations found in patients with
aHUS have functional consequences.
Patients, Material, and Methods
Patients and Control Individuals
Three patients with aHUS who carry missense mu-
tations in the HF1 gene and three unaffected control
individuals were selected for the present studies. The
clinical and genetic data on the patients are depicted in
table 1. In brief, patient HUS2 is heterozygous for the
W1183L mutation. Despite the HF1 mutation, patient
HUS2 presented with normal complement profiles, and,
interestingly, his plasma factor H levels were significantly
elevated. Patient HUS29 is heterozygous for the R1210C
mutation. Levels of factor H in patient HUS29 are at
the lower end of the normal range. C3 levels were also
slightly decreased. HUS2 and HUS29 plasmas are ex-
pected to contain a mixture of wild-type and mutant
factor H proteins. Patient HUS3, who also has a factor
H missense mutation (V1197A), is the only patient, in
the series of patients with aHUS whom we studied, who
had half-normal levels of factor H and a moderate hy-
pocomplementemia with decreased AP50 and C3 levels.
Genetic analyses demonstrated that the two copies of
the factor H gene were mutated in patient HUS3 (Pe´rez-
Caballero et al. 2001). One copy carries a deletion that
is incompatible with expression of factor H, and the
second copy carries the V1197A mutation in SCR20. As
a consequence of these defects, patient HUS3 presents
both—factor H deficiency and a V1197A mutant factor
H that, in addition, should be the only factor H protein
in the plasma of this patient. The V1197A mutation,
like the R1210C mutation, seems to be a recurrent factor
H mutation. It has also been found in heterozygosis in
two other patients with aHUS in two independent stud-
ies (Caprioli et al. 2001; Richards et al. 2001).
Three control individuals, denoted as “N1,” “N2,” and
“N3,” were included in these studies. Two of them were
selected from a panel of unaffected individuals, for being
homozygotes for the two major factor H polymorphic
variants (Rodrı´guez de Co´rdoba and Rubinstein 1984).
N1 is an HF1*1 (Tyr402) homozygote, and N2 is an
HF1*2 (His402) homozygote. Serum and EDTA-blood
samples were obtained from patients and control in-
dividuals after informed consent was obtained. EDTA
plasma (10 ml) was prepared by centrifugation at 4C
and was kept frozen at 20C until used.
Factor H Purification
Five to ten milliliters of EDTA plasma were dia-
lysed against Tris-HCl (20 mM; pH 7.5) and NaCl
(50 mM) and were applied to a heparin-Sepharose
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Table 1
Complement Profiles and Factor H Levels in Patients with aHUS
PATIENT (AGE) CLINICAL HISTORYa
LEVELS OF COMPLEMENT COMPONENTS
AND FUNCTIONAL ACTIVITIESb
HF1
MUTATIONSCH50 AP50
C3
(77–210 mg/dl)
C4
(14–47 mg/dl)
H
(17–50 mg/dl)
HUS2 (25 years) CRF, transplanted twice, hemodialysis N N 71 30 116 W1183L
HUS3 (55 years) CRF, hemodialysis N L 59 26 11c V1197Ac
HUS29 (14 mo) Recurrences, CRF, peritoneal dialysis ND ND 58 28.5 19.8 R1210C
a CRF p chronic renal failure.
b Measured in serum samples. Complement activity was determined by hemolytic assays using antibody-sensitized sheep erythrocytes (CH50)
or rabbit erythrocytes (AP50). C3 and C4 concentrations were determined by nephelometry (Immage, Beckmann). Factor H was quantitated
by a sandwich ELISA, using goat polyclonal antibodies (Quidel) and a murine monoclonal antibody (Quidel), and by semiquantitative western
blot analyses, as described elsewhere (Sa´nchez-Corral et al. 2000). N p normal value; L p low; ND p not done.
c Heterozygous for an HF1 null allele.
column. After extensive washes with dialysis buffer,
the proteins bound to the column were eluted with
an NaCl gradient (50–500 mM). Fractions containing
factor H were identified by ELISA, were pooled, were
dialysed against Tris-HCl (20 mM; pH 7.5) and NaCl
(150 mM), and were incubated overnight at 4C with
Sepharose beads coated with a mouse monoclonal
anti–human factor H antibody (35H9). Factor H was
eluted from the Sepharose-35H9 column with NaSCN
(3 M). NaSCN was removed from the eluate by using
a Sephadex G-25 column, and the factor H sample
was dialysed against Tris-HCl (20 mM; pH 7.5) and
NaCl (50 mM) and was loaded into a Mono-Q col-
umn (HR 5/5; Amersham Biosciences). Factor H was
eluted with an NaCl (50–500 mM) gradient and the
fractions containing factor H were identified by SDS-
PAGE. Factor H–albumin complexes were purified
from factor H by using an anti-HSA (human serum
albumin)–Sepharose column.
Expression and Purification of Recombinant Proteins
The full-length human factor H cDNA (3,926 bp; En-
trez-Nucleotide accession number Y00716) was intro-
duced in the eukaryote expression vector pCINeo (Stra-
tagene). The aHUS-associated HF1 mutation W1183L
was created in the HF1-pCINeo construct through site-
directed mutagenesis, by using a commercial kit from
Stratagene. The HF1 insert in the W1183L-pCINeo con-
struct was completely sequenced in both strands, to con-
firm that no other mutations were present. Plasmid DNA
was prepared using “concert maxipreps” (GibcoBRL)
columns. COS7 cells grown in Dulbecco’s modified Ea-
gle medium supplemented with 10% fetal calf serum
(GibcoBRL) were transfected with the HF1-pCINeo or
W1183L-pCINeo constructs, by using lipofectin (Gibco-
BRL). Transfected cells were cultured in the presence of
1 mg/ml G-418 sulfate (Geneticin; GibcoBRL), and re-
sistant cells were cloned by limiting dilution. Individual
clones secreted factor H to the culture media at concen-
trations ranging from 0.2 to 2 mg/ml. Factor H recom-
binant proteins expressed in COS7 cells were purified
from the cultured cells’ supernatants by following the
same protocol as that used to purify factor H from hu-
man plasma.
PAGE and Immunoblotting
PAGE in the presence of SDS was performed using the
buffer system described by Laemmli (1970). Reduction of
samples was achieved in the presence of 700 mM b-mer-
captoethanol (Sigma), and incubation was achieved at
100C for 5 min. Gels were stained with 1% Coomassie
brilliant blue R-250 (Sigma) or with 12 mM silver nitrate
reagent. Western blot analysis was performed on nitro-
cellulose membranes, by using anti–factor H monoclonal
antibody 35H9, as described elsewhere (Sa´nchez-Corral
et al. 2000).
Fluid-Phase C3b Cofactor-Activity Assay
The fluid-phase cofactor activity of factor H was de-
termined in a C3b proteolytic assay (Fujita and Nus-
senzweig 1979), using purified proteins. In brief, differ-
ent amounts (10, 50, and 250 ng) of purified factor H
were added to 2 mg of C3b and 0.4 mg of factor I and
were incubated at 37C for 1 h in Tris-HCl (20 mM;
pH 7.5) and NaCl (150 mM). Proteolysis of C3b was
determined by analyzing the cleavage of the a′ chain and
the generation of the a65, a45, and a43 fragments using
8% SDS-PAGE under reducing conditions. Human C3
was purified from plasma, and C3b was generated by
limited trypsin digestion (Sa´nchez-Corral et al. 1989).
Factor I was a generous gift of Dr. R. Sim (MRC Im-
munochemistry Unit, Oxford University, Oxford, United
Kingdom).
Surface-Bound C3b–Binding Assay
The binding of factor H to surface-bound C3b was
determined using an ELISA method. In brief, 96-well
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Figure 2 Electrophoretic analysis of control and aHUS-associ-
ated factor H proteins. All samples included in the present analyses
were run nonreduced in 8% polyacrylamide gels in the presence of
SDS. a, 8% polyacrylamide gel stained with 1% Coomassie, to illus-
trate that no differences were observed between the factor H proteins
purified from control individuals N1 and N2 (1 mg) and patients HUS2
and HUS3 (2 mg). b, 8% polyacrylamide gel stained with 1% Coomas-
sie, showing that two protein bands, of 210 kDa and 155 kDa (factor
H), were copurified from patient HUS29. c, Western blot using the
35H9 monoclonal anti–factor H antibody, to illustrate that the two
protein bands purified from patient HUS29 are recognized as factor
H. Factor H purified from control individual N3 was used as a ref-
erence of wild-type factor H in this experiment.
polystyrene microtiter plates (Costar) were coated
overnight at 4C with 0.4 mg of purified C3b in 100
ml of coupling buffer (0.1 M NaHCO3 [pH 9.5]).
Plates were washed once in TNT buffer (50 mM Tris/
HCl [pH 7.4], 150 mM NaCl, and 0.2% Tween 20),
and the wells were blocked with 1% BSA in TNT
buffer for 1 h at room temperature. After the washing
in TNT buffer, purified factor H at different concen-
trations in 100 ml of 1% BSA in TNT buffer was added
to each well in duplicate and was allowed to interact
with the surface-bound C3b for 1 h at room temper-
ature. After four washes in TNT buffer, 100 ml of a
rabbit anti–human factor H polyclonal antibody gen-
erated in the laboratory was added to each well and
was incubated for 1 h at room temperature. This an-
tibody lacks reactivity against human C3b. After three
washes in TNT buffer, 100 ml of a 1/1,000 dilution
of goat anti–rabbit immunoglobulin G antibody cou-
pled with horseradish peroxidase (DAKO) was added
and kept for 30 min at room temperature. The plates
were washed five times, the enzymatic reaction was
developed with OPD (DAKO) and was stopped with
0.1 M H2SO4, and absorbance was determined by
reading at 492 nm. The concentration of the factor
H preparations used in these experiments was deter-
mined in duplicates of the samples added to the C3b-
coated plates in a parallel ELISA using the rabbit
anti–factor H polyclonal antibody and the monoclo-
nal antibody 35H9.
Results and Discussion
Although genetic studies have clearly demonstrated
the involvement of the complement regulator factor
H in aHUS and many different HF1 mutations have
already been identified in a significant number of pa-
tients, the precise role that factor H plays in the path-
ogenesis of aHUS is still unknown. To get further
insight into the molecular basis of aHUS and to char-
acterize the functional consequences of the aHUS-
associated factor H mutations, we selected three pa-
tients with aHUS (HUS2, HUS3, and HUS29) and
three control individuals (N1, N2, and N3) (see the
“Patients, Material, and Methods” section) and pu-
rified their factor H to homogeneity. Isolation of fac-
tor H from EDTA-plasma samples was achieved in
three chromatographic steps: heparin-Sepharose col-
umn, affinity chromatography using the anti–factor
H monoclonal antibody 35H9, and fast protein liq-
uid chromatography on a Mono-Q column. All of
the factor H proteins were obtained with similar
yields and presented with a comparable degree of
purification. During the purification procedures, we
observed that the factor H present in the aHUS plas-
mas was fully retained in the heparin-Sepharose col-
umn and that it was eluted as a single peak with the
NaCl gradient. Moreover, the elution profiles in the
three patients with aHUS and the three control plas-
mas were identical.
Analysis of the purified proteins by SDS-PAGE did not
show any differences between the molecular sizes of the
W1183L and V1197A aHUS-associated and control fac-
tor H proteins (fig. 2a). However, the SDS-PAGE analysis
of the factor H proteins purified from the R1210C het-
erozygotes showed two bands, of 155 kDa and 210 kDa,
respectively. Both bands present comparable intensities
when stained with 1% Coomassie (fig. 2b), and both are
equally well recognized by monoclonal and polyclonal
anti–human factor H antibodies in western blot exper-
iments (fig. 2c). The R1210C mutation has previously
been reported in two unrelated Italian patients with
aHUS—one familial and one sporadic (Caprioli et al.
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Figure 3 Segregation of the R1210C mutation in family HUS29. a, Pedigree of family HUS29, illustrating the segregation of the R1210C
mutation. Levels of factor H in plasma are indicated for each member of the family. Nonaffected R1210C carriers are shown in gray. Seven
SNPs in the factor H gene, including one in the promoter region (331T/C), were analyzed to determine the segregation of the maternal and
paternal factor H alleles in the patient and her sister, but the mother was homozygous for the seven SNPs. b, Western blot analysis of 1 ml of
plasma from each HUS29 family member by using the anti–human factor H monoclonal antibody 35H9. Plasma samples are not reduced. The
positions of the two factor H bands are indicated with arrows. Notice the decreased levels of both factor H alleles in the patient (IV-1).
2001). In the three pedigrees, incomplete penetrance of
the disease and a characteristic high-molecular-weight
factor H band in R1210C carriers are observed (fig. 3)
(Caprioli et al. 2001). The 210-kDa factor H band seg-
regates with the R1210C mutation in four generations
in the HUS29 family, suggesting that this high-molecular-
weight band corresponds to the product of the R1210C
mutant factor H allele (fig. 3). To further characterize the
210-kDa factor H band, we analyzed the factor H protein
purified from R1210C heterozygotes in SDS-PAGE under
reducing conditions (fig. 4a). These analyses revealed the
presence of an additional protein band with an electro-
phoretic mobility comparable to that of HSA (65 kDa),
suggesting that the 210-kDa band results from the co-
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Figure 4 Characterization of the high-molecular-weight factor H associated with the R1210C mutation. a, 10% SDS-PAGE of the factor
H (fH) proteins purified from patient HUS29 and control individual N3. Samples were reduced with 10% b-mercaptoethanol. A gel stained
with 1% Coomassie is shown. b, Western blot analyses of reduced and nonreduced factor H proteins purified from patient HUS29 and control
individual N3, using a rabbit anti-HSA polyclonal antibody. c, SDS-PAGE analysis of the wild-type (H29R; flow through) and mutated (H29C;
retained) factor H proteins purified from patient HUS29, using anti-HSA affinity chromatography. Samples were not reduced. A silver-stained
10% polyacrylamide gel is shown.
valent interaction between factor H and HSA. Western
blot analyses of the factor H proteins purified from
patient HUS29 demonstrated that, in fact, the 210-kDa
band is recognized by a polyclonal antibody against HSA
and that, on reduction with b-mercaptoethanol, the 65-
kDa protein band that originates from the 210-kDa band
is recognized by these antibodies as HSA (fig. 4b).
Interestingly, the factor H R1210C mutation described
here is very similar to that responsible for the anomalous
C1 inhibitor (C1-INH) protein reported by Laurell and
Ma˚rtensson (1971) in a patient with angioneurotic ede-
ma. In that report, an abnormal C1-INH protein di-
sulfide bonded to serum albumin—known as “Da muta-
tion”—also resulted from a missense mutation that
changes an arginine residue at position 444 to cysteine
(Laurell and Ma˚rtensson 1971; Skriver et al. 1989). The
C1-INH–albumin heterodimers lack the capacity that
normal C1-INH has in the inhibition of the activated
C1 complexes (Laurell and Ma˚rtensson 1971).
Similar to the case of the C1-INH Da mutation, on
the basis of the analyses of the factor H proteins pu-
rified from the R1210C carriers, we conclude that the
high-molecular-weight factor H band present in the
plasma of the R1210C heterozygotes results from the
covalent interaction between factor H and HSA, most
likely through the additional cysteine residue at position
1210. These findings allowed us to purify the products
of the mutated factor H allele (210-kDa band; denoted
as “H29C”) and the normal factor H allele (155-kDa
band; denoted as “H29R”) in the factor H preparations
from patient HUS29, by affinity chromatography using
an anti-HSA antibody (fig. 4c).
The capacity that the factor H proteins purified from
the patients with aHUS and unaffected individuals have
to control activation of the complement system was es-
timated using two different assays—analysis of the co-
factor-activity of factor H in the proteolysis of fluid-
phase C3b by factor I and analysis of the binding of
factor H to surface-bound C3b.
The factor H proteins purified from patients HUS2 and
HUS3 presented normal cofactor activity in the prote-
olysis of fluid-phase C3b by factor I. These activities were
indistinguishable from the activity of the factor H pro-
teins purified from the control individuals (fig. 5). Sim-
ilarly, the cofactor activities of the two factor H alleles
of patient HUS29 (H29R and H29C) were normal and
comparable to the control proteins (fig. 5).
The recombinant factor H proteins purified from
the COS7 cells’ culture supernatants—wild-type and
W1183L mutant factor H—also presented cofactor
activity that was comparable to the activity of the
factor H proteins purified from plasma (fig. 5). These
analyses indicate that the recombinant factor H pro-
teins produced in COS7 cells are fully active and that
the W1183L mutation has no effect on the cofactor
activity.
As a whole, these data suggest that patients with aHUS
who carry the W1183L, V1197A, and R1210C muta-
tions in factor H have normal capacity to control ac-
tivation of the complement in plasma. This is in agree-
ment with the clinical laboratory findings in most
patients with aHUS who show complement profiles in
plasma that would be incompatible with a classical fac-
tor H deficiency (Pe´rez-Caballero et al. 2001). Since
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Figure 5 Analysis of the cofactor activity of factor H in the proteolysis of fluid-phase C3b by factor I. a, Analysis by 8% SDS-PAGE
under reducing conditions of the proteolysis of C3b by factor I in the presence of factor H. Factor H samples include purified factor H from
two control individuals (N1 and N2), purified factor H from patients with aHUS (HUS2 [H2] and HUS3 [H3]), purified factor H corresponding
to the wild-type (H29R) and mutated (H29C) alleles of patient HUS29, and purified recombinant wild-type factor H (r-factor H) and W1183L
mutant factor H (r-W1183L) expressed in COS7 cells. Each panel includes three different concentrations of factor H. Identification of the C3b
fragments is depicted in the panel corresponding to N2. The cofactor activity of factor H results in cleavage of the a′ chain of C3b in the
fragments a65 and a45/a43. The top left panel corresponds to the control lanes of C3b alone and C3b plus factor I in the absence of factor
H. b, Densitometric analysis of the proteolysis of C3b by factor I in the presence of factor H. Stained gels were scanned in a GS-800 Calibrated
Densitometer (Bio-Rad), and the bands were quantified with ImageQuant, version 3.3 (Molecular Dynamics). The percentage of the C3b cleavage
was determined as the ratio of the values corresponding to the a65 and the a′ bands. The code for the samples is indicated at bottom.
V1197A mutant factor H is the only factor H in the
plasma of patient HUS3, these data also indicate that
the moderate hypocomplementemia in HUS3 is prob-
ably unrelated to the V1197A mutation and is most
likely due to this patient’s carrying a null HF1 allele
and presenting half-normal levels of factor H.
In contrast with the apparently normal cofactor ac-
tivity, the ability of the factor H proteins to interact
with surface-bound C3b in the three aHUS-associated
factor H proteins is highly diminished as compared with
the three control factor H proteins (fig. 6a). The C3b-
binding assay is a simple test that measures direct bind-
ing of purified factor H to purified C3b immobilized on
microtiter plates (see the “Patients, Material, and Meth-
ods” section). In this assay, a reduced binding of factor
H to the microtiter wells indicates that the factor H has
reduced capacity to bind surface-bound C3b or, alter-
natively, that not all of the factor H present in the
factor H preparation has capacity to bind to surface-
bound C3b.
The V1197A mutant factor H should be the only factor
H protein in the plasma of patient HUS3, and, thus, the
decreased binding of the factor H preparation from this
patient to the C3b-coated plates (fig. 6a) is interpreted
as a decreased binding of the mutant V1197A factor H
protein to the surface-bound C3b. Similarly, figure 6a
shows that the purified factor H–albumin heterodimers
(H29C) do not bind to surface-bound C3b, whereas the
product of the wild-type allele (H29R) in the R1210C
heterozygotes binds normally to the C3b-coated plates.
Binding of serum albumin to the regions of factor H that
are needed to interact with surface-bound C3b (SCR20)
most likely represents a serious steric hindrance that
makes these surfaces inaccessible and prevents binding
of the factor H–albumin heterodimers to the C3b-coated
plates.
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Figure 6 Binding of factor H to surface-bound C3b. a, Analysis
of factor H purified from plasma. Included were purified factor H from
three control individuals (N1, N2, and N3), purified factor H from
patients with aHUS (HUS2 [H2] and HUS3 [H3]), and purified factor
H corresponding to the wild-type (H29R) and mutated (H29C) factor
H alleles of patient HUS29. In the present analyses, the concentration
of factor H ranged between 50 and 500 ng/ml. The results are expressed
as the percentage of the binding observed for factor H from the control
individual N3 at 500 ng/ml. Values are the mean  SD of at least three
independent experiments. b, Analysis of recombinant factor H proteins,
showing the binding of purified recombinant wild-type factor H (r-fH)
and W1183L mutant factor H (r-W1183L). Two different concentrations
of recombinant factor H were used. The results are expressed as the
percentage of the binding observed for recombinant wild-type factor H
(r-fH) at the highest concentration. Values are the mean  SD of at
least three independent experiments.
In contrast, the reduced factor H binding to the C3b-
coated plates that was observed in the case of the factor
H preparations from patient HUS2 (fig. 6a) most likely
indicates that not all of the factor H present in these
samples has capacity to bind to surface-bound C3b.
These data were interpreted as suggesting that the mu-
tant W1183L factor H protein has impaired interac-
tion with surface-bound C3b. In agreement with this
conclusion, the recombinant W1183L mutant factor
H protein shows a significantly lower capacity to bind
to surface-bound C3b than the recombinant wild-type
factor H protein does (fig. 6b), providing direct evi-
dence that this mutation interferes with the interaction
between factor H and surface-bound C3b.
As a whole, these results represent the first evidence of
a functional defect in the factor H associated with aHUS
and illustrate a potential limitation, in the three patients
with aHUS, to control complement activation on cellular
surfaces. It is remarkable that, despite showing an im-
paired interaction with surface-bound C3b, the recom-
binant W1183L mutant factor H produced in COS7
cells shows more capacity to bind to surface-bound C3b
than the factor H preparations from patient HUS2 do
(fig. 6). This is most likely related to the fact that all of
the recombinant factor H proteins produced in COS7
cells show much more affinity for surface-bound C3b
than the equivalent proteins purified from plasma do.
Whether this increased affinity is a consequence of dif-
ferent factor H glycosylation in COS7 cells is presently
unknown.
On the basis of structural predictions, it has recently
been proposed that aHUS-associated factor H mutations
may result in the failure of the mutant factor H to in-
teract with polyanionic cell surfaces, therefore prevent-
ing activation of the alternative pathway of complement
activation on these surfaces (Perkins and Goodship
2002). The data reported here clearly demonstrate that
the factor H preparations from patients with aHUS who
carry different mutations show decreased binding to
surface-bound C3b as compared with unaffected con-
trol individuals. Whether impaired recognition of sur-
face-bound C3b by factor H is a common feature among
aHUS-associated mutations is presently unknown. The
findings reported here may offer a simple test, to dis-
tinguish between normal and functionally impaired
factor H, that will improve the molecular diagnosis of
aHUS, complementing the mutational analysis of the
HF1 gene.
The patients with aHUS who are included in the pres-
ent studies carry factor H mutations—two of which are
in heterozygosis—that cause loss of binding of factor H
to surface-bound C3b. This suggests that development
of aHUS requires activation of the complement system
and implies that factor H functional haploinsufficiency
results in an inefficient protection of the cellular sur-
faces. According to these ideas, a suboptimal concen-
tration of wild-type factor H in patients with aHUS,
which is perhaps sufficient to control basal complement
activation, upon a situation that triggers complement
activation (i.e., infection, immune complexes, cytotoxic
drugs, etc.), cannot maintain the integrity of the micro-
vasculature cell membranes and results in tissue damage
and destruction. It has recently been shown that mice
with factor H deficiency and uncontrolled C3 activa-
tion develop membranoproliferative glomerulonephri-
tis (Pickering et al. 2002). Interestingly, these animals,
which show severe hypocomplementemia, do not de-
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velop aHUS, supporting the idea that aHUS requires
an active complement system.
Family HUS29 also illustrates that the aHUS pheno-
type cannot be fully explained only on the basis of the
presence of a single factor H genetic mutation. Figure 3
shows that, in this pedigree, there are five members, in
addition to the patient, who carry the R1210C mutation
in heterozygosis but that none of them has been affected
by the disease. Similar findings have been observed in
other pedigrees with aHUS that carry this and other
mutations in the factor H gene (Warwicker et al. 1998;
Caprioli et al. 2001; Pe´rez-Caballero et al. 2001).
The incomplete penetrance of the disease in carriers of
the factor H mutation suggests that aHUS is a complex
disorder that involves environmental influences, genetic
modifier loci, or a combination of both of these factors.
Infection, pregnancy, toxins, immune complexes, and cy-
totoxic or immunosuppressive drugs are probably among
the environmental factors triggering aHUS.
The von Willebrand factor cleaving protease
(ADAMTS13) deficiency could be one of the genetic
factors contributing to the aHUS phenotype (Remuzzi
et al. 2002a). In patient HUS29, however, tests to assess
for von Willebrand factor have been normal, including
testing for multimers (data not shown). Genetic factors
determining variations in the plasma levels of factor H
could also explain the incomplete penetrance that the
disease has in R1210C carriers in the HUS29 pedigree
studied here. In this respect, whereas factor H levels are
at the lower part of the normal range (19.8 mg/dl) in
patient HUS29, factor H levels are at the higher part
of or above the normal range (42.3–58.3 mg/dl) in the
nonaffected R1210C carriers in the HUS29 pedigree.
Interestingly, the mother of patient HUS29 shows in-
termediate plasma levels of factor H (32.5 mg/dl). The
possibility that the intermediate plasma levels of factor
H in the mother and the decreased factor H levels in
the patient could be due to the presence of a low-ex-
pression factor H maternal allele segregating to the pa-
tient seems unlikely, because expression of both factor
H alleles in the patient is decreased as compared with
other R1210C carriers (fig. 3b). However, it is possible
that genetic factors influencing the plasma levels of
factor H contribute to the pathogenesis of aHUS. In
an unaffected individual, the threefold range of vari-
ation in the factor H plasma concentration (17–50 mg/
dl) is probably irrelevant, but in an individual carrying
an aHUS-associated mutant factor H allele in hetero-
zygosis, a two- to threefold reduction in the total levels
of plasma factor H could be critical.
Reduced plasma levels of factor H are not a general
explanation of the incomplete penetrance of the dis-
ease in carriers of factor H mutations and are in ap-
parent contradiction with cases such as that in patient
HUS2, whose plasma factor H levels are significantly
elevated over the normal range (table 1). We believe
that an extended half-life of the mutant factor H pro-
tein in plasma could result in a reduction in the pro-
portion of the wild-type factor H; this reduction
would account for both the unexpectedly low bind-
ing, to surface-bound C3b, of the HUS2 factor H
preparations and the increased plasma levels of factor
H in this patient. We are currently designing exper-
iments to determine the proportion of wild-type fac-
tor H in the plasma of patient HUS2. Additionally,
it would be interesting to investigate whether an im-
paired interaction between factor H and surface-bound
C3b alters the clearance of factor H from plasma.
Although there is currently no definitive explanation
for the incomplete penetrance of aHUS in carriers of the
factor H mutations, the analysis of the HUS29 pedigree
and the functional characterization of the factor H aHUS-
associated mutations reported here reinforce the current
view (Caprioli et al. 2001; Pe´rez-Caballero et al. 2001;
Richards et al. 2001), which is that exogenous admin-
istration of wild-type factor H or other complement in-
hibitors should be considered as a potential treatment for
aHUS. In fact, at age 14 mo, patient HUS29, who had
three recurrences of HUS since the initial presentation at
age 6 mo and progressed to end-stage kidney disease, has
had no relapses (hematologic) in 4 mo of treatment with
weekly fresh-frozen plasma infusions. Moreover, a recent
work by Remuzzi et al. (2002b) reports the success of a
combined liver and kidney transplantation in a patient
with aHUS who carries the W1183R factor H mutation,
further supporting the factor H replacement therapy.
In conclusion, our results demonstrate that the com-
plement regulatory protein factor H, purified from three
patients with aHUS, has impaired recognition of sur-
face-bound C3b. These findings are in accordance with
the hypothesis that patients with aHUS have a specific
dysfunction in the protection of cellular surfaces from
complement activation. Although these studies justify
the exogenous administration of wild-type factor H to
the patients with aHUS, further analysis will be needed
to determine whether impaired recognition of surface-
bound C3b by factor H is a common feature among
patients with aHUS and to explain the incomplete pen-
etrance of the disease in carriers of aHUS-associated
factor H mutations.
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